MedAlliance's Selution DCB Granted FDA Breakthrough Device Designation

 

February 28, 2019—MedAlliance SA, a Switzerland-based medical technology company, announced that it has been granted FDA Breakthrough Device designation for Selution, the company's sustained limus release (SLR) drug-coated balloon (DCB) catheter for the treatment of coronary artery disease.

According to MedAlliance, the FDA received the company's request to designate Selution as a Breakthrough Device in January 2019. The proposed indications for use include improving luminal diameter, after predilatation, in the treatment of coronary artery in-stent restenosis for stenotic lengths up to 36 mm with reference vessel diameters of 2.25 to 4.5 mm.

The company stated that under the Breakthrough Device Program, the FDA will provide MedAlliance with priority review and interactive communication regarding device development and clinical trial protocols, through to commercialization decisions. The goal of the program is to provide patients and health care providers with timely access to designated medical devices by speeding their development, assessment, and review, while preserving the statutory standards for premarket approval, 510(k) clearance, and de novo marketing authorization that are consistent with the FDA's mission to protect and promote public health.

MedAlliance noted that the Selution SLR DCB features microreservoirs made from biodegradable polymer intermixed with sirolimus. The microreservoirs provide controlled and sustained release of sirolimus, with an extended release profile similar to that of a drug-eluting stent. Preclinical animal data showed therapeutic levels of sirolimus in tissue for > 60 days, and first-in-human clinical trial results in peripheral arteries demonstrated a late lumen loss of 0.19 mm.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.